



Docket No. 58404 (71432)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: C. Thru et al.

Serial No.: 10/717,434

GROUP: 1632

Filed: November 18, 2003

For: ANTISENSE DESIGN

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is **mandatory**.)

(Express Mail certification is optional.)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on this date **July 27, 2004**, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number **EV438993457US**, addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Mail Stop Missing Parts.

Lee Dunkle

(type or print name of person mailing paper)

Signature of person mailing paper

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2) within three months of the mailing date of the Search Report issued by the **European Patent Office** (dated) (**COPY ENCLOSED**); or
- (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or

C. Thru et al.

Serial No.: 10/717,434

Page 2

_____ (4) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

 X are enclosed herewith; or
_____ have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



Christine C. O'Day (Reg. 38,256)
Edwards & Angell, LLP
P.O. Box 55874
Boston, MA 02205
(617) 439-4444

Date: July 27, 2004

FORM PTO-1449		DOCKET NO.: 58404 (71432)		SERIAL NO.: 10/717,434			
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): c. Thru et al.					
		FILING DATE: November 18, 2003		GROUP NO.: 1632			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	AA	WO 99/14226	03/25/99	WIPO			
	AB	WO 98/39352	09/11/98	WIPO			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	AC	Nielsen et al., <i>J. Chem. Soc., Perkin Trans. I</i> , pp. 3423-3433 (1997).					
	AD	Nielsen et al., <i>Chem. Commun.</i> , 9:825-826 (1997).					
	AE	Christensen et al., <i>J. Am. Chem. Soc.</i> , 120:5458-5463 (1998).					
	AF	Koshkin et al., <i>J. Org. Chem.</i> , 63(8):2778-2781 (1998).					
	AG	Koshkin et al., <i>J. Am. Chem. Soc.</i> 120(50):13252-13253 (1998).					
	AH	Kumar et al., <i>Bioorg. & Med. Chem. Lett.</i> , 8:2219-2222 (1998).					
	AI	Braasch et al., <i>Biochemistry</i> , 41(14):4503-4510 (2002).					
	AJ	Crinelli et al., <i>Nucl. Acid. Res.</i> , 30(11):2435-2443 (2002).					
	AK	Elayadi et al., <i>Biochemistry</i> , 41:9973-9981 (2002).					
	AL	Jacobsen et al., <i>Nucl. Acid. Res.</i> , 30(19), in press (2002).					
	AM	Kurreck et al., <i>Nucl. Acid. Res.</i> , 30(9):1911-1918 (2002).					
	AN	Obika et al., <i>Bioorg. & Med. Chem.</i> , 9:1001-1011 (2001).					
	AO	Braasch et al., <i>Chem. & Biol.</i> , 55:1-7 (2000).					
	AP	Wahlestedt et al., <i>PNAS</i> , 97(10):5633-5638 (2000).					
	AQ	Freier et al., <i>Nucl. Acid Res.</i> , 25(22):4429-4443 (1997).					
	AR	Cook, <i>Nucleosides & Nucleotides</i> , 18(6&7), 1141-62 (1999).					
	AS	Singh, <i>J. Org. Chem.</i> , 63:6078-6079 (1998).					
	AT	Singh et al. <i>J. Org. Chem.</i> , 63:10035-10039 (1998).					
	AU	Rajwanshi et al., <i>J. Chem Commun.</i> , pp. 2073-2074 (1999).					
	AV	Hakansson et al., <i>Bioorg Med Chem Lett</i> , 11:935-938 (2001).					
	AW	Rajwanshi et al., <i>Chem Commun.</i> , pp. 1395-1396 (1999).					
	AX	Wengel et al., <i>Nucleosides, Nucleotides & Nucleic Acids</i> , 20(4-7):389-396 (2001).					
	AY	Rajwanshi et al., <i>Angew. Chem. Int. Ed.</i> , 39(9):1656-1659 (2000).					
	AZ	Petersen et al., <i>J. Am. Chem. Soc.</i> , 123:7431-7432 (2001).					
	BA	Sørensen et al., <i>J. Am. Chem. Soc.</i> , 124(10):2164-2176 (2002).					
	BB	Vester et al., <i>J. Am. Chem. Soc.</i> , 124(46):13682-13683 (2002).					
	BC	Arzumanov et al., <i>Biochemistry</i> 40:14645-14654 (2001).					
	BD	Zamecnik et al., <i>PNAS</i> , 75(1):280-284 (1978).					
	BE	Bennet et al., <i>Biochim. Biophys. Acta</i> , 1489:19-30 (1999).					
	BF	Crooke, <i>Biotechnol. Genet. Eng. Rev.</i> , 15:121-57 (1998).					
	BG	Wengel, <i>J. In Antisense Drug Technology; Principles</i> , pp. 339-355 (2001).					
	BH	Simeonov et al., <i>Nucleic Acids Research</i> , 30(17), in press (2002).					
	BI	Childs et al., <i>PNAS</i> , 99(17):11091-11096 (2002).					
Examiner:					Date:		